1700019O17Rik activators encompass a diverse set of chemical compounds that enhance the functional activity of the protein through various cellular signaling pathways. For instance, Forskolin and Dibutyryl-cAMP (db-cAMP) both raise intracellular cAMP levels, leading to activation of PKA. This kinase is then able to phosphorylate specific substrates that could include 1700019O17Rik itself or proteins within its signaling pathway, therefore enhancing 1700019O17Rik's activity. Likewise, calcium ionophores like Ionomycin and A-23187 elevate intracellular calcium, which may activate calcium-dependent proteins and signaling pathways that involve 1700019O17Rik, leading to its activation. Phorbol 12-myristate 13-acetate (PMA) specifically activates PKC, which could result in the phosphorylation of 1700019O17Rik or proteins in associated pathways, whereas Sphingosine-1-phosphate engages G-protein-coupled receptors to initiate signaling cascades that could ultimately enhance 1700019O17Rik function.
The molecular landscape of 1700019O17Rik activation is further influenced by compounds that modulate various kinase activities. Epigallocatechin gallate (EGCG), a known kinase inhibitor, may selectively inhibit kinases that negatively regulate 1700019O17Rik, thereby promoting its activity. Similarly, the broad-spectrum kinase inhibitor Staurosporine may inadvertently enhance 1700019O17Rik signaling by inhibiting kinases that suppress its pathway. The PI3K inhibitor LY294002 potentially redirects signaling pathways to favor those involving 1700019O17Rik, leading to its enhanced activity. Retinoic acid, through its action on gene expression, might indirectly increase the functional activity of pathways in which 1700019O17Rik participates. In the MAPK/ERK pathway, U0126 serves as an MEK inhibitor, which could also result in the indirect activation of 1700019O17Rik by altering the pathway's dynamics. Lastly, Rapamycin, by inhibiting mTOR, could activate compensatory pathways that serve to enhance 1700019O17Rik's function, illustrating the intricate web of cellular signaling that converges on the activation of this protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations, which can modify the activity of calcium-dependent proteins, possibly including 1700019O17Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may lead to phosphorylation of 1700019O17Rik or associated proteins, thereby enhancing 1700019O17Rik function. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate interacts with its receptors to initiate signaling cascades that could culminate in the activation of 1700019O17Rik through downstream effectors. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A-23187 acts as a calcium ionophore, promoting calcium influx that could activate calcium-dependent signaling pathways involving 1700019O17Rik. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid modulates gene expression through its receptors, which might enhance the activity of proteins involved in the same pathways as 1700019O17Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that might preferentially inhibit kinases that negatively regulate 1700019O17Rik, thereby enhancing the protein's activity. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
db-cAMP is a cAMP analog that activates PKA, potentially leading to the phosphorylation and activation of 1700019O17Rik or proteins within its pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could shift signaling pathways to favor those involving 1700019O17Rik, leading to its enhanced activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that might preferentially inhibit kinases in competing pathways, indirectly enhancing the pathway of 1700019O17Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which could lead to the activation of alternative pathways that enhance the function of 1700019O17Rik. | ||||||